🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Taiwan / NCT06215404
Recruiting Not applicable

Fluid Management Strategies on Blood Loss in Liver Transplantation

NCT06215404 · tracked via the Priya Life Science Taiwan tracker
Phase
Not applicable
Started
2024-01-15
Last updated
2025-04-11

Condition(s) studied

Liver Transplant

Investigational drug(s) / intervention(s)

Liberal grouprestrictive group

Liberal group: Fluid challage to keep stroke volume variation \< 10%

restrictive group: Fluid challage to keep stroke volume variation \< 18%

Study summary

During liver transplantation, due to the complexity of the operation and abnormal coagulation function, there may be a large amount of bleeding and corresponding blood transfusion. Excessive blood transfusion will increase pulmonary complications and affect the prognosis. Infusion management to reduce bleeding is a very important issue in liver transplant surgery. Restrictive infusion management can effectively reduce the amount of bleeding in liver transplantation, but it remains unclear whether it will cause sequelae in other major organs.

The investigators plan to study different infusion goals and strategies in liver transplant surgery using a randomized group model, using the PiCCO (Pulse Contour Cardiac Output) cardiopulmonary volume monitor, and setting the stroke volume variation (SVV) as the macroscopic circulation.The purpose of this study was to divide it into restrictive and liberal groups to explore the impact on liver transplantation bleeding volume and inflammatory response as well as postoperative lung and renal function, and to collect statistics on clinical care and postoperative sequelae (pulmonary liver, renal function impairment, etc.) in order to develop the most appropriate infusion management strategy in liver transplantation.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * end stage liver disease * age between 18y/o to 75 y/o * expected to recieve to receive liver transplantation Exclusion Criteria: * arrythmia

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
National Taiwan University Hospital Taipei Taiwan Recruiting

More National Taiwan University Hospital trials in Taiwan

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06215404 on ClinicalTrials.gov ↗ ← All trials in Taiwan